Last reviewed · How we verify

NCT04933149

Ketamine Infusion for Treatment of Chronic Neuropathic Pain in Traumatic Brachial Plexus Injuries, a Prospective Randomized Control Study

ENROLLING BY INVITATION Phase 4 Last updated 21 April 2026
What this trial tests

Phase 4 trial testing Ketamine Infustion in Brachial Plexus Injury in 100 participants. Enrolling by invitation.

Timeline
15 December 2021
Primary endpoint
1 December 2026
1 December 2026

Quick facts

Lead sponsorMayo Clinic
PhasePhase 4
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment100
Start date15 December 2021
Primary completion1 December 2026
Estimated completion1 December 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Brachial Plexus Injury. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The purpose of this study is to assess pre- and postoperative neuropathic pain in patients with traumatic brachial plexus injuries to determine if intraoperative ketamine infusion affect neuropathic pain associated with avulsion injuries of the brachial plexus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04933149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing